First-Generation ASOs in Angelman Syndrome: A Promising Start, With Room to Improve | REACH MarketVue®

Based on in-depth interviews with ten Angelman syndrome specialists - including pediatric geneticists, pediatric neurologists, a developmental behavioral pediatrician, and a psychiatrist - REACH’s MarketVue® research dives into the key questions that will impact uptake of the first wave of disease modifying therapies.

Three Critical Gaps To Address For Angelman Syndrome Patients and Families

Communication: The Outcome That Matters Most to Families

Ask any specialist what families want most from a disease-modifying therapy, and the answer is immediate. Communication, specifically expressive language, sits above everything else on the priority list.

Both pivotal trials for emerging ASOs (Ultragenyx’s GTX-102 and Ionis’ ION582) anchor on the Bayley-4 raw score; where they differ is the primary subdomain; Ultragenyx has selected cognition, while Ionis has selected expressive communication. Clinically, that split is narrower than it looks, because specialists view cognition and expressive communication as closely linked in Angelman syndrome, with gains in one tending to track the other. KOLs nonetheless voice a preference for Ionis’s use of expressive communication as the primary measure, since speech is the outcome families rate as most meaningful. Another consequence of the divergence is for cross-trial comparison because the differing subdomains will be difficult to compare.

Convenience: The Barrier That Grows With Every Repeat Administration

KOLs interviewed by REACH acknowledged that intrathecal (IT) administration is a burden that can be managed following in the footsteps of a path charted by SMA specialists with Spinraza, but they were equally clear about the access inequities and burden on patients and families that the delivery route creates. Families in rural areas or without proximity to an academic center capable of administering lumbar punctures under sedation face a practical access ceiling. But access is only half the problem: repeat lumbar punctures under sedation impose an ongoing burden on patients and caregivers that accumulates with every dose.

For any entrant arriving after the first ASO approval, convenience will be a key area for improvement. REACH’s research quantifies the specific dimensions of convenience that specialists and caregivers weigh against efficacy, and the answer is not uniform across patient subgroups.

Eligibility: The Genotypes and Ages Current Trials Leave Behind

Beyond what a therapy does, there is the question of whom it can reach. On both genotype and age, the first-generation ASO trials draw boundaries that leave meaningful patient populations out.

By genotype, roughly 88% of Angelman syndrome patients carry either a maternal deletion (~75%) or a UBE3A mutation (~15%); the remaining ~10% - those with uniparental disomy (UPD) or imprinting center defects (ICD) - are excluded from the pivotal ASO trials over theoretical concerns about overexpression when paternal UBE3A unsilencing is applied to patients who already express some residual protein.

The specialist community is more divided on that exclusion than the trial designs suggest: several KOLs interviewed by REACH argued the real-world overexpression risk in UPD and ICD patients has been overstated, and that these milder-phenotype patients may be among those with the most to gain. A therapy proven safe and effective across all genotypes would occupy a distinct clinical and commercial position from one that is not.

Age draws the second boundary. Both GTX-102 (4–17 in Aspire) and ION582 (2–50 in HALOS) enroll adolescents and, in Ionis’s case, adults; yet clinicians describe a genuine tension: they expect the greatest cognitive gains from early intervention, but are not ready to write off older patients, who may still benefit in behavioral and attentional domains. The adult population is especially underserved - adult neurologists are often unfamiliar with the condition, therapy coverage tends to end when school does, and the transition out of pediatric care is described by every KOL as a structural failure rather than a clinical one.

Taken together, genotype and age define a novel therapy’s addressable population: one built to reach all genotypes and all ages would be differentiating vs the narrower inclusion criteria of current late-stage therapies.

A Landscape in Motion: How the Standard of Care Will Shift

Today, the standard of care remains symptomatic management only, with no DMTs approved - antiepileptics, melatonin and neuroleptics for sleep, behavioral therapy and limited pharmacotherapy for behavior, PT/OT/SLP for developmental support. Looking ahead to 2027–2030, first ASO approvals offer a modest first step and a new access problem: GTX-102 (Ultragenyx) anticipated approval mid-to-late 2027, with ION582 (Ionis) potentially a year later assuming the pivotal data hold. If approved, first-generation ASOs will become the default for newly diagnosed patients, but adoption will concentrate in academic centers and repeat IT administration will remain a structural barrier for a meaningful share of families. 2030 and beyond, gene replacement raises the bar on both efficacy and simplicity: MavriX’s MVX-220 (one-time ICM injection, AAV UBE3A gene replacement) anticipated in phase 3 data around 2030, with potential approval ~2032. Preclinical models demonstrate 60–90% wild-type UBE3A brain expression. KOLs set expectations meaningfully above what ASOs have delivered and the irreversibility of gene therapy demands it.

The Bottom Line

The treatment landscape in Angelman syndrome is moving from an era of zero disease-modifying options to potentially multiple disease-modifying options. That transition increases the bar for differentiation. By the time a second-generation ASO or gene therapy reaches approval, the clinical community will have formed views on what “good” looks like based on the first data they actually lived with in practice. REACH’s MarketVue® report defines that bar precisely including the specific thresholds across cognition, communication, behavioral, and sleep domains that specialists expect a novel therapy to clear relative to ASO benchmarks.